L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.
L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.
复制标题
DOI：
--
复制
发表时间：
2015-03
影响因子：
5.3
通讯作者：
Qian Wang;J. Holst
中科院分区：
文献类型：
--
作者：
Qian Wang;J. Holst
l型氨基酸转运蛋白（LAT）家族是不依赖于Na（+）的转运蛋白，将中性氨基酸输送到细胞中。四个lat， LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 （SLC43A1）和LAT4 (SLC43A2)，负责大部分细胞亮氨酸摄取。它们在许多癌症中表达增加，并且对通过mTORC1途径控制蛋白质翻译和细胞生长至关重要。在癌症中观察到的转运蛋白表达增加是由转录途径如激素受体、c-myc和营养饥饿反应调节的。我们回顾了LAT1家族在癌症中的表达和功能，以及针对LAT1或LAT3的特异性抑制剂的最新进展。这些LAT家族抑制剂可能是多种癌症有用的辅助治疗药物。
The L-type amino acid transporter (LAT) family are Na(+)-independent transporters, which deliver neutral amino acids into cells. The four LATs, LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 (SLC43A1) and LAT4 (SLC43A2), are responsible for the majority of cellular leucine uptake. They show increased expression in many cancers, and are critical for control of protein translation and cell growth through the mTORC1 pathway. The increased transporter expression observed in cancers is regulated by transcriptional pathways such as hormone receptors, c-myc and nutrient starvation responses. We review the expression and function of the LAT family in cancer, as well as the recent development of specific inhibitors targeting LAT1 or LAT3. These LAT family inhibitors may be useful adjuvant therapeutics in multiple cancers.